PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 32166573-10 2020 Noteworthy, a higher concentration of RSV (25 microM) exhibited an additive effect on levels of phosphorylated forms of ERK1/2, and p38MAPK, as well as an increased activity of the Na+-K+-Cl- co-transporter-1 (NKCC1), factors known to induce astrocytes swelling, when the cells were treated with ammonia or after trauma or ischemia. Resveratrol 38-41 mitogen-activated protein kinase 3 Homo sapiens 120-126 32166573-11 2020 Further, inhibition of ERK1/2, and p38MAPK diminished the RSV-induced exacerbation of cell swelling post-ammonia, trauma and OGD treatment. Resveratrol 58-61 mitogen-activated protein kinase 3 Homo sapiens 23-29 32326308-10 2020 Unrelated activities of DHT and resveratrol that originate at integrin depend upon downstream stimulation of mitogen-activated protein kinase (MAPK, ERK1/2) activity, suggesting the existence of distinct, function-specific pools of ERK1/2 within the cell. Resveratrol 32-43 mitogen-activated protein kinase 3 Homo sapiens 149-155 32186753-0 2020 Resveratrol rescues TNF-alpha-induced inhibition of osteogenesis in human periodontal ligament stem cells via the ERK1/2 pathway. Resveratrol 0-11 mitogen-activated protein kinase 3 Homo sapiens 114-120 32186753-9 2020 Further mechanistic studies indicated that resveratrol exerted anti-inflammatory activity by activating the ERK1/2 pathway, decreasing the secretion of interleukin (IL)-6 and IL-8 induced by TNF-alpha, and enhancing hPDLSCs osteogenesis. Resveratrol 43-54 mitogen-activated protein kinase 3 Homo sapiens 108-114 32326308-10 2020 Unrelated activities of DHT and resveratrol that originate at integrin depend upon downstream stimulation of mitogen-activated protein kinase (MAPK, ERK1/2) activity, suggesting the existence of distinct, function-specific pools of ERK1/2 within the cell. Resveratrol 32-43 mitogen-activated protein kinase 3 Homo sapiens 232-238 32326402-10 2020 Mechanistically, using the HCC827-HUVEC co-culture model, we showed that RSVL-suppressed ENG expression was accompanied with augmented levels of phosphorylated extracellular signal-regulated kinase (ERK) 1/2 and increased tubule network formation, which may explain why RSVL promoted tumor microvessel growth in vivo. Resveratrol 73-77 mitogen-activated protein kinase 3 Homo sapiens 160-207 30941654-0 2019 Resveratrol inhibits the proliferation of estrogen receptor-positive breast cancer cells by suppressing EZH2 through the modulation of ERK1/2 signaling. Resveratrol 0-11 mitogen-activated protein kinase 3 Homo sapiens 135-141 31406997-8 2019 Collectively, dietary resveratrol could have beneficial effects to regulate innate immunity and inflammatory response, via inhibiting the activation of NF-kappaB, MAPK, and PI3K/AKT signaling pathways induced by heat stress in the spleen. Resveratrol 22-33 mitogen-activated protein kinase 3 Homo sapiens 163-167 30941654-9 2019 The suppression of EZH2 expression by ERK1/2 dephosphorylation is important for the antiproliferative activities of resveratrol against ER-positive breast cancer cells. Resveratrol 116-127 mitogen-activated protein kinase 3 Homo sapiens 38-44 30066962-6 2019 Inhibition of PP2A with okadaic acid or overexpression of dominant-negative PP2A rendered resistance to resveratrol"s suppression of the basal or IGF-1-stimulated phospho-Erk1/2 and cell adhesion, whereas expression of wild-type PP2A enhanced resveratrol"s inhibitory effects. Resveratrol 104-115 mitogen-activated protein kinase 3 Homo sapiens 171-177 30066962-0 2019 Resveratrol inhibits Erk1/2-mediated adhesion of cancer cells via activating PP2A-PTEN signaling network. Resveratrol 0-11 mitogen-activated protein kinase 3 Homo sapiens 21-27 30066962-3 2019 Here, we show that resveratrol suppressed the basal or type I insulin-like growth factor (IGF)-1-stimulated adhesion of cancer cells (Rh1, Rh30, HT29, and HeLa cells) by inhibiting the extracellular signal-regulated kinase 1/2 (Erk1/2) pathway. Resveratrol 19-30 mitogen-activated protein kinase 3 Homo sapiens 228-234 30066962-4 2019 Inhibition of Erk1/2 with U0126, knockdown of Erk1/2, or overexpression of dominant-negative mitogen-activated protein kinase kinase 1 (MKK1) strengthened resveratrol"s inhibition of the basal or IGF-1-stimulated of Erk1/2 phosphorylation and cell adhesion, whereas ectopic expression of constitutively active MKK1 attenuated the inhibitory effects of resveratrol. Resveratrol 155-166 mitogen-activated protein kinase 3 Homo sapiens 14-20 30066962-4 2019 Inhibition of Erk1/2 with U0126, knockdown of Erk1/2, or overexpression of dominant-negative mitogen-activated protein kinase kinase 1 (MKK1) strengthened resveratrol"s inhibition of the basal or IGF-1-stimulated of Erk1/2 phosphorylation and cell adhesion, whereas ectopic expression of constitutively active MKK1 attenuated the inhibitory effects of resveratrol. Resveratrol 155-166 mitogen-activated protein kinase 3 Homo sapiens 46-52 30066962-4 2019 Inhibition of Erk1/2 with U0126, knockdown of Erk1/2, or overexpression of dominant-negative mitogen-activated protein kinase kinase 1 (MKK1) strengthened resveratrol"s inhibition of the basal or IGF-1-stimulated of Erk1/2 phosphorylation and cell adhesion, whereas ectopic expression of constitutively active MKK1 attenuated the inhibitory effects of resveratrol. Resveratrol 155-166 mitogen-activated protein kinase 3 Homo sapiens 46-52 30066962-5 2019 Further research revealed that both protein phosphatase 2A (PP2A) and phosphatase and tensin homolog (PTEN)-Akt were implicated in resveratrol-inactivated Erk1/2-dependent cell adhesion. Resveratrol 131-142 mitogen-activated protein kinase 3 Homo sapiens 155-161 31434965-6 2019 Notably, the polyphenolic phytoalexin resveratrol, inhibited uPAR expression and consequently the signaling molecules ERK1/2 downstream of EGFR thus revealing additive effects on promoting OSCC cetuximab-sensitivity in vitro and in vivo. Resveratrol 38-49 mitogen-activated protein kinase 3 Homo sapiens 118-124 30066962-7 2019 Overexpression of wild-type PTEN or dominant-negative Akt or inhibition of Akt with Akt inhibitor X strengthened resveratrol"s inhibition of the basal or IGF-1-stimulated Erk1/2 phosphorylation and cell adhesion. Resveratrol 113-124 mitogen-activated protein kinase 3 Homo sapiens 171-177 30066962-8 2019 Furthermore, inhibition of mechanistic/mammalian target of rapamycin (mTOR) with rapamycin or silencing mTOR enhanced resveratrol"s inhibitory effects on the basal and IGF-1-induced inhibition of PP2A-PTEN, activation of Akt-Erk1/2, and cell adhesion. Resveratrol 118-129 mitogen-activated protein kinase 3 Homo sapiens 225-231 30066962-9 2019 The results indicate that resveratrol inhibits Erk1/2-mediated adhesion of cancer cells via activating PP2A-PTEN signaling network. Resveratrol 26-37 mitogen-activated protein kinase 3 Homo sapiens 47-53 30693838-0 2018 Resveratrol provides neuroprotective effects through modulation of mitochondrial dynamics and ERK1/2 regulated autophagy. Resveratrol 0-11 mitogen-activated protein kinase 3 Homo sapiens 94-100 29555649-3 2018 The mechanism of resveratrol action requires nuclear accumulation of inducible cyclooxygenase (COX)-2 and its complexation with phosphorylated ERK1/2. Resveratrol 17-28 mitogen-activated protein kinase 3 Homo sapiens 143-149 29514046-0 2018 Resveratrol stimulates c-Fos gene transcription via activation of ERK1/2 involving multiple genetic elements. Resveratrol 0-11 mitogen-activated protein kinase 3 Homo sapiens 66-72 30018026-8 2018 The protein kinase extracellular signal-regulated protein kinase ERK1/2 was identified to function as signal transducer connecting resveratrol stimulation with the activation of NF-kappaB and IL-8 promoter-controlled transcription. Resveratrol 131-142 mitogen-activated protein kinase 3 Homo sapiens 65-71 29439139-10 2018 Additionally, though the ERK1/2 pathway was significantly activated in the mechanical compression group, resveratrol partly attenuated activation of the ERK1/2 pathway under mechanical compression in a dose-dependent manner. Resveratrol 105-116 mitogen-activated protein kinase 3 Homo sapiens 153-159 29514046-11 2018 Pharmacological and genetic experiments revealed that the protein kinase ERK1/2 is the signal transducer that connects resveratrol treatment with the c-Fos gene. Resveratrol 119-130 mitogen-activated protein kinase 3 Homo sapiens 73-79 29268122-0 2018 Resveratrol and pinostilbene confer neuroprotection against aging-related deficits through an ERK1/2-dependent mechanism. Resveratrol 0-11 mitogen-activated protein kinase 3 Homo sapiens 94-100 29268122-5 2018 While DA and its metabolites (DOPAC and HVA), dopamine transporter, and tyrosine hydroxylase levels remain unchanged during aging or treatment, resveratrol and pinostilbene increased ERK1/2 activation in vitro and in vivo in an age-dependent manner. Resveratrol 144-155 mitogen-activated protein kinase 3 Homo sapiens 183-189 29268122-7 2018 These data suggest that resveratrol and pinostilbene alleviate age-related motor decline via the promotion of DA neuronal survival and activation of the ERK1/2 pathways. Resveratrol 24-35 mitogen-activated protein kinase 3 Homo sapiens 153-159 29439139-0 2018 Resveratrol attenuates mechanical compression-induced nucleus pulposus cell apoptosis through regulating the ERK1/2 signaling pathway in a disc organ culture. Resveratrol 0-11 mitogen-activated protein kinase 3 Homo sapiens 109-115 28759712-5 2017 Resveratrol and hormone-induced signals are both transduced by activated extracellular-regulated kinases 1 and 2 (ERK1/2); however, hormones promote cell proliferation, while resveratrol induces antiproliferation in cancer cells. Resveratrol 0-11 mitogen-activated protein kinase 3 Homo sapiens 114-120 29241073-0 2018 Resveratrol inhibits proliferation, migration and invasion via Akt and ERK1/2 signaling pathways in renal cell carcinoma cells. Resveratrol 0-11 mitogen-activated protein kinase 3 Homo sapiens 71-77 29242151-3 2018 Treatment with resveratrol leads to phosphorylation and nuclear translocation of mitogen-activated protein kinase (ERK1/2), and accumulation of nuclear COX-2 to complex with pERK1/2 and p53. Resveratrol 15-26 mitogen-activated protein kinase 3 Homo sapiens 115-121 29242151-6 2018 Resveratrol treatment caused nuclear accumulation and complexing of ERK1/2, pSer15-p53 and COX-2 which was activated ERK1/2-dependent. Resveratrol 0-11 mitogen-activated protein kinase 3 Homo sapiens 68-74 29242151-6 2018 Resveratrol treatment caused nuclear accumulation and complexing of ERK1/2, pSer15-p53 and COX-2 which was activated ERK1/2-dependent. Resveratrol 0-11 mitogen-activated protein kinase 3 Homo sapiens 117-123 27829129-4 2016 Exposure to resveratrol decreased EGFR and downstream kinases Akt and ERK1/2 activation. Resveratrol 12-23 mitogen-activated protein kinase 3 Homo sapiens 70-76 28759712-9 2017 Results suggest that nonpeptide hormones inhibit resveratrol-induced antiproliferation in cancer cells downstream of the interaction between ligand and receptor and ERK1/2 activation to interfere with nuclear COX-2 accumulation. Resveratrol 49-60 mitogen-activated protein kinase 3 Homo sapiens 165-171 28759712-10 2017 Thus, the surface receptor sites for resveratrol and nonpeptide hormones are distinct and can induce discrete ERK1/2-dependent downstream antiproliferation biological activities. Resveratrol 37-48 mitogen-activated protein kinase 3 Homo sapiens 110-116 28495310-7 2017 In addition, PM induced Akt, ERK1/2, or p38 MAPK activation, which was inhibited by resveratrol. Resveratrol 84-95 mitogen-activated protein kinase 3 Homo sapiens 44-48 28666466-14 2017 RSV increased Erk1/2 phosphorylation in OA Ob; however, it had no effect on Smad 1/5/8 phosphorylation. Resveratrol 0-3 mitogen-activated protein kinase 3 Homo sapiens 14-20 28666466-20 2017 CONCLUSION: These data indicate that RSV promotes Sirt1 levels, inhibits the endogenous expression of leptin by OA osteoblasts and can promote the Wnt/beta-catenin and Erk1/2 signaling pathways, which are altered in these cells. Resveratrol 37-40 mitogen-activated protein kinase 3 Homo sapiens 168-174 27677845-6 2016 Furthermore, resveratrol inhibits NTHi-induced ERK1/2 phosphorylation by increasing MKP-1 expression via a cAMP-PKA-dependent signaling pathway. Resveratrol 13-24 mitogen-activated protein kinase 3 Homo sapiens 47-53 27863838-2 2016 Present study is aimed to preliminarily evaluate our hypothesis that the combination of resveratrol (RSV), a natural antioxidant, and lower dose of sorafenib (SF), a multi-kinase inhibitor and a component of ERK1/2 (extracellular signal-regulated kinase 1/2) pathway, would augment apoptosis in human breast cancer MCF7 cells. Resveratrol 88-99 mitogen-activated protein kinase 3 Homo sapiens 208-214 27588384-10 2016 Moreover, inhibition of ERK1/2 phosphorylation by ferulic acid and resveratrol contributed to cell growth inhibition. Resveratrol 67-78 mitogen-activated protein kinase 3 Homo sapiens 24-30 27528888-7 2016 Orthovanadate, a protein tyrosine phosphatase inhibitor, and Resveratrol (Resv), an antioxidant agent, protected FAK and ERK1/2 from dephosphorylation and HUVEC from ROS-induced loss of adhesion. Resveratrol 61-65 mitogen-activated protein kinase 3 Homo sapiens 121-127 27042433-7 2015 Here we show that RSV inhibits adhesion, proliferation and migration of EPN cells, and that these effects are associated to induction of dose- and time-dependent p66Shc-Ser36 phosphorylation and ERK1/2 de-phosphorylation. Resveratrol 18-21 mitogen-activated protein kinase 3 Homo sapiens 195-201 26851786-7 2016 In the case of molecules in MEK/ERK signaling pathway, the expression of Ras, Raf, MEK and ERK1/2 was decreased significantly in resveratrol groups with a dose-dependent manner. Resveratrol 129-140 mitogen-activated protein kinase 3 Homo sapiens 91-97 26046675-0 2015 Resveratrol Enhances Etoposide-Induced Cytotoxicity through Down-Regulating ERK1/2 and AKT-Mediated X-ray Repair Cross-Complement Group 1 (XRCC1) Protein Expression in Human Non-Small-Cell Lung Cancer Cells. Resveratrol 0-11 mitogen-activated protein kinase 3 Homo sapiens 76-82 25296980-6 2014 RES+CUR compared to CUR increased the PARP-1 cleavage, the Bax/Bcl-2 ratio, the inhibition of ERK1 and ERK2 phosphorylation, and the expression of LC3 II simultaneously with the formation of autophagic vacuoles. Resveratrol 0-4 mitogen-activated protein kinase 3 Homo sapiens 94-98 26456774-4 2015 Resveratrol and DHT signals are both transduced by activated ERK1/2; however, DHT promotes cell proliferation in cancer cells, whereas resveratrol is pro-apoptotic. Resveratrol 0-11 mitogen-activated protein kinase 3 Homo sapiens 61-67 26456774-12 2015 Thus, the surface receptor sites for resveratrol and DHT are discrete and activate ERK1/2-dependent downstream effects on apoptosis that are distinctive. Resveratrol 37-48 mitogen-activated protein kinase 3 Homo sapiens 83-89 26146868-0 2015 Resveratrol prevents cadmium activation of Erk1/2 and JNK pathways from neuronal cell death via protein phosphatases 2A and 5. Resveratrol 0-11 mitogen-activated protein kinase 3 Homo sapiens 43-49 26146868-7 2015 Over-expression of PP2A or PP5 strengthened the inhibitory effects of resveratrol on Cd-induced activation of Erk1/2 and/or JNK, as well as cell death. Resveratrol 70-81 mitogen-activated protein kinase 3 Homo sapiens 110-116 26146868-8 2015 The results indicate that resveratrol prevents Cd-induced activation of Erk1/2 and JNK pathways and neuronal cell death in part via activating PP2A and PP5. Resveratrol 26-37 mitogen-activated protein kinase 3 Homo sapiens 72-78 25701505-6 2015 Furthermore, the inhibitory action of these pro-inflammatory mediators occurred through an inhibition of MAPKs (ERK1/2, p38 and JNK) and NF-kappaB signaling pathways based on a toll-like receptor 4 in macrophages, which may be closely mediated with the radiolysis products of resveratrol transformed by gamma-irradiation. Resveratrol 276-287 mitogen-activated protein kinase 3 Homo sapiens 112-118 25542083-7 2015 Blocking this ERK1/2-mediated temozolomide and curcumin induced autophagy with resveratrol, a blood-brain barrier permeable drug, improved temozolomide/curcumin efficacy in brain-implanted tumors. Resveratrol 79-90 mitogen-activated protein kinase 3 Homo sapiens 14-20 25540919-6 2015 RSV, like NADPH oxidase inhibitor diphenyleneiodonium, can block ERK1/2 activation induced by high glucose. Resveratrol 0-3 mitogen-activated protein kinase 3 Homo sapiens 65-71 25540919-7 2015 Our results demonstrate that RSV is a potent agent against high glucose-induced EMT in renal tubular cells via inhibition of NADPH oxidase/ROS/ERK1/2 pathway. Resveratrol 29-32 mitogen-activated protein kinase 3 Homo sapiens 143-149 27528888-7 2016 Orthovanadate, a protein tyrosine phosphatase inhibitor, and Resveratrol (Resv), an antioxidant agent, protected FAK and ERK1/2 from dephosphorylation and HUVEC from ROS-induced loss of adhesion. Resveratrol 61-72 mitogen-activated protein kinase 3 Homo sapiens 121-127 25929783-6 2015 In addition, resveratrol inhibited the over-expression of p-AKT and p-ERK1/2. Resveratrol 13-24 mitogen-activated protein kinase 3 Homo sapiens 70-76 25401496-9 2015 In addition, the results indicated that resveratrol inhibited the phosphorylation of c-Jun N-terminal kinase (JNK)1/2 and extracellular-signal-regulated kinase (ERK)1/2 involved in downregulating protein expression and the transcription of MMP-9. Resveratrol 40-51 mitogen-activated protein kinase 3 Homo sapiens 122-168 25401496-10 2015 CONCLUSION: In summary, resveratrol inhibited MMP-9 expression and oral cancer cell metastasis by downregulating JNK1/2 and ERK1/2 signals pathways and, thus, exerts beneficial effects in chemoprevention. Resveratrol 24-35 mitogen-activated protein kinase 3 Homo sapiens 124-130 25865632-0 2015 Activation of ERK1/2 is required for the antimitotic activity of the resveratrol analogue 3,4,5,4"-tetramethoxystilbene (DMU-212) in human melanoma cells. Resveratrol 69-80 mitogen-activated protein kinase 3 Homo sapiens 14-20 24971582-9 2014 Furthermore, resveratrol (10 muM) attenuated HG-induced phosphorylation of Akt, p38 mitogen-activated protein kinase (MAPK), ERK 1/2, and JNK1/2 without affecting total levels. Resveratrol 13-24 mitogen-activated protein kinase 3 Homo sapiens 118-122 24971582-9 2014 Furthermore, resveratrol (10 muM) attenuated HG-induced phosphorylation of Akt, p38 mitogen-activated protein kinase (MAPK), ERK 1/2, and JNK1/2 without affecting total levels. Resveratrol 13-24 mitogen-activated protein kinase 3 Homo sapiens 125-132 24971582-11 2014 CONCLUSIONS: Resveratrol inhibits HG-induced oxidative stress and VSMC proliferation by suppressing ROS generation, NADPH oxidase, Akt phosphorylation, p38 MAPK/JNK/ERK phosphorylation, and IkappaB-alpha and NF-kappaB activities. Resveratrol 13-24 mitogen-activated protein kinase 3 Homo sapiens 156-160 22878646-5 2012 In the present study, we defined the signaling pathways modulated by resveratrol in ischemia by examining SIRT1 expression and phosphorylation of Akt, ERK1/2 and p38 in the ischemic cortex. Resveratrol 69-80 mitogen-activated protein kinase 3 Homo sapiens 151-157 24079413-7 2013 Interestingly, treatment with resveratrol abolished POVPC-induced phosphorylation of Cx43 as a result of inhibiting activation of Src, MEK, and ERK1/2. Resveratrol 30-41 mitogen-activated protein kinase 3 Homo sapiens 144-150 23954321-7 2013 Importantly, the combination treatment with RES and 5-FU induced a remarkably synergistic enhancement of growth inhibition and apoptosis through the additional suppression of the MAPK/Erk1/2 signaling pathway in colon cancer DLD-1 cells. Resveratrol 44-47 mitogen-activated protein kinase 3 Homo sapiens 179-183 23954321-7 2013 Importantly, the combination treatment with RES and 5-FU induced a remarkably synergistic enhancement of growth inhibition and apoptosis through the additional suppression of the MAPK/Erk1/2 signaling pathway in colon cancer DLD-1 cells. Resveratrol 44-47 mitogen-activated protein kinase 3 Homo sapiens 184-190 24095720-3 2013 To unravel this mechanism, using HEK293 cells as a model, we found that resveratrol inhibited the ERK1/2 activation triggered by Ca2+ store depletion. Resveratrol 72-83 mitogen-activated protein kinase 3 Homo sapiens 98-104 24095720-7 2013 Although additional targets for resveratrol in the molecular mechanism that governs SOCE cannot be discarded, the present results demonstrate that ERK1/2 pathway is a major target for resveratrol, and that the impairment of its activation produces a significant inhibition of SOCE. Resveratrol 184-195 mitogen-activated protein kinase 3 Homo sapiens 147-153 23495037-8 2013 In summary, resveratrol and ceramide converge on an endocytosis-requiring, ERK1/2-dependent signal transduction pathway and induction of COX-expression as an essential molecular antecedent for subsequent p53-dependent apoptosis. Resveratrol 12-23 mitogen-activated protein kinase 3 Homo sapiens 75-81 22878646-6 2012 Resveratrol increased expression of SIRT1 and phosphorylation of Akt and p38 but inhibited the increase in phosphorylation of ERK1/2. Resveratrol 0-11 mitogen-activated protein kinase 3 Homo sapiens 126-132 23464396-11 2012 The PKC- ERK1/2 signaling pathway can partially mediate resveratrol-induced apoptosis of HT-29 cells. Resveratrol 56-67 mitogen-activated protein kinase 3 Homo sapiens 9-15 22234583-7 2012 We also showed that resveratrol reduces phosphorylation levels of the extracellular signal-regulated kinase (ERK) 1/2. Resveratrol 20-31 mitogen-activated protein kinase 3 Homo sapiens 70-117 21856773-6 2011 Resveratrol-induced cell-cycle arrest and apoptosis occurred in association with induction of p38 MAPK phosphorylation and suppression of ERK1/2 signaling pathway. Resveratrol 0-11 mitogen-activated protein kinase 3 Homo sapiens 98-102 23464396-8 2012 Western blotting showed that e phosphorylation of PKCalpha and ERK1/2 was significantly increased in response to resveratrol treatment. Resveratrol 113-124 mitogen-activated protein kinase 3 Homo sapiens 63-69 21856773-6 2011 Resveratrol-induced cell-cycle arrest and apoptosis occurred in association with induction of p38 MAPK phosphorylation and suppression of ERK1/2 signaling pathway. Resveratrol 0-11 mitogen-activated protein kinase 3 Homo sapiens 138-144 20626463-7 2010 The effect of resveratrol on the proliferation of HaCaT cells and the activation of ERK1/2, AKT, and p66Shc was investigated by cell counting, fluorescence-activated cell sorting, and western blot analysis of total or immunoprecipitated cell extracts. Resveratrol 14-25 mitogen-activated protein kinase 3 Homo sapiens 84-90 21419119-0 2011 Extracellular HIV-1 Tat upregulates TNF-alpha dependent MCP-1/CCL2 production via activation of ERK1/2 pathway in rat hippocampal slice cultures: inhibition by resveratrol, a polyphenolic phytostilbene. Resveratrol 160-171 mitogen-activated protein kinase 3 Homo sapiens 96-102 21419119-10 2011 Resveratrol, to a level similar to that of SL327, downregulated Tat-induced proinflammatory responses via the inactivation of ERK1/2. Resveratrol 0-11 mitogen-activated protein kinase 3 Homo sapiens 126-132 21419119-12 2011 Additionally, the inhibition of Tat-induced production of MCP-1 and TNF-alpha via the inactivation of the ERK1/2 pathway may represent the anti-inflammatory mechanism of resveratrol in the hippocampus. Resveratrol 170-181 mitogen-activated protein kinase 3 Homo sapiens 106-112 21187340-2 2011 Resveratrol induces programmed cell death (apoptosis) in these cells and activates important signal transducing proteins including extracellular signal-regulated kinases (ERKs) 1 and 2 in cancer cells. Resveratrol 0-11 mitogen-activated protein kinase 3 Homo sapiens 171-175 21187340-8 2011 Nuclear accumulation of activated ERK1/2 and sumolyated COX-2 are essential to resveratrol-induced pSer-15-p53-mediated apoptosis in human ovarian cancer cells. Resveratrol 79-90 mitogen-activated protein kinase 3 Homo sapiens 34-40 21484156-0 2011 Curcumin synergizes with resveratrol to stimulate the MAPK signaling pathway in human articular chondrocytes in vitro. Resveratrol 25-36 mitogen-activated protein kinase 3 Homo sapiens 54-58 21484156-3 2011 In this study, we investigated whether curcumin and resveratrol can synergistically inhibit the catabolic effects of IL-1beta, specifically the inhibition of the MAPK and subsequent apoptosis in human articular chondrocytes. Resveratrol 52-63 mitogen-activated protein kinase 3 Homo sapiens 162-166 21484156-8 2011 Furthermore, curcumin and resveratrol inhibited IL-1beta- or U0126-induced apoptosis and downregulation of beta1-integrins and Erk1/2 in human articular chondrocytes. Resveratrol 26-37 mitogen-activated protein kinase 3 Homo sapiens 127-133 21261644-3 2011 Resveratrol treatment in vitro causes activation and nuclear translocation of mitogen-activated protein kinase (ERK1/2), consequent phosphorylation of Ser-15 of p53, and apoptosis. Resveratrol 0-11 mitogen-activated protein kinase 3 Homo sapiens 112-118 21261644-7 2011 NS-398, a specific pharmacologic inhibitor of COX-2, prevents resveratrol-induced complexing of nuclear ERK1/2 with COX-2 and with pSer-15-p53 and subsequent apoptosis; cyclooxygenase enzyme activity is not involved. Resveratrol 62-73 mitogen-activated protein kinase 3 Homo sapiens 104-110 21261644-9 2011 Epidermal growth factor, estrogen, and thyroid hormone act downstream of ERK1/2 to prevent resveratrol-induced apoptosis. Resveratrol 91-102 mitogen-activated protein kinase 3 Homo sapiens 73-79 20626463-8 2010 In HaCaT cells, resveratrol induces dose- and time-dependent growth arrest, p66Shc-Ser36 phosphorylation, ERK1/2 phosphorylation and AKT dephosphorylation. Resveratrol 16-27 mitogen-activated protein kinase 3 Homo sapiens 106-112 20626463-9 2010 Finally, we showed that resveratrol-induced p66Shc-Ser36 phosphorylation is dependent on ERK1/2 activation. Resveratrol 24-35 mitogen-activated protein kinase 3 Homo sapiens 89-95 18656273-3 2009 On the other hand, pretreatment with the polyphenolic stilbene resveratrol (RSVL, 1-100 microM) triggered more prominent inhibition of ET-1-evoked cell proliferation and ERK1/2 activation. Resveratrol 76-80 mitogen-activated protein kinase 3 Homo sapiens 170-176 20082299-6 2010 Resveratrol-enhanced perforin expression and cytotoxic activity are effectively inhibited by pretreatment with the inhibitors of JNK (SP600125), ERK-1/2 (PD98059), or by siRNAs against JNK-1 and ERK-2. Resveratrol 0-11 mitogen-activated protein kinase 3 Homo sapiens 145-152 20082299-11 2010 Data presented strongly indicate that resveratrol act via NKG2D-dependent JNK and ERK-1/2 pathways. Resveratrol 38-49 mitogen-activated protein kinase 3 Homo sapiens 82-89 22966330-7 2010 Furthermore, in resveratrol-treated glioma cells, pretreatment with P38 or ERK1/2 inhibitors reduced the autophagic level, suggesting that resveratrol-induced autophagy was positively regulated by P38 and the ERK1/2 pathway. Resveratrol 16-27 mitogen-activated protein kinase 3 Homo sapiens 75-81 22966330-7 2010 Furthermore, in resveratrol-treated glioma cells, pretreatment with P38 or ERK1/2 inhibitors reduced the autophagic level, suggesting that resveratrol-induced autophagy was positively regulated by P38 and the ERK1/2 pathway. Resveratrol 16-27 mitogen-activated protein kinase 3 Homo sapiens 209-215 22966330-7 2010 Furthermore, in resveratrol-treated glioma cells, pretreatment with P38 or ERK1/2 inhibitors reduced the autophagic level, suggesting that resveratrol-induced autophagy was positively regulated by P38 and the ERK1/2 pathway. Resveratrol 139-150 mitogen-activated protein kinase 3 Homo sapiens 75-81 22966330-7 2010 Furthermore, in resveratrol-treated glioma cells, pretreatment with P38 or ERK1/2 inhibitors reduced the autophagic level, suggesting that resveratrol-induced autophagy was positively regulated by P38 and the ERK1/2 pathway. Resveratrol 139-150 mitogen-activated protein kinase 3 Homo sapiens 209-215 20090934-0 2010 Modulation of Akt and ERK1/2 pathways by resveratrol in chronic myelogenous leukemia (CML) cells results in the downregulation of Hsp70. Resveratrol 41-52 mitogen-activated protein kinase 3 Homo sapiens 22-28 20090934-8 2010 Resveratrol significantly modulated ERK1/2 activity as evident from hyper phosphorylation at T302/Y304 residues and simultaneous upregulation in kinase activity. Resveratrol 0-11 mitogen-activated protein kinase 3 Homo sapiens 36-42 20090934-10 2010 Therefore, increase in ERK1/2 activity by Resveratrol provided another negative influence on Hsp70 levels through negative regulation of HSF1 activity. Resveratrol 42-53 mitogen-activated protein kinase 3 Homo sapiens 23-29 20090934-13 2010 Simultaneously treating K562 with Resveratrol and 17AAG maintained phosho-ERK1/2 levels close to untreated controls demonstrating their opposite effects on ERK1/2 pathway. Resveratrol 34-45 mitogen-activated protein kinase 3 Homo sapiens 74-80 20090934-13 2010 Simultaneously treating K562 with Resveratrol and 17AAG maintained phosho-ERK1/2 levels close to untreated controls demonstrating their opposite effects on ERK1/2 pathway. Resveratrol 34-45 mitogen-activated protein kinase 3 Homo sapiens 156-162 20090934-15 2010 CONCLUSION/SIGNIFICANCE: Thus our study comprehensively illustrates that Resveratrol acts downstream of Bcr-Abl and inhibits Akt activity but stimulates ERK1/2 activity. Resveratrol 73-84 mitogen-activated protein kinase 3 Homo sapiens 153-159 18656273-8 2009 These results demonstrate a novel signaling pathway for RSVL that leads from activation of the pGC/kinase-G system to inhibition of ERK1/2 and their downstream nuclear targets. Resveratrol 56-60 mitogen-activated protein kinase 3 Homo sapiens 132-138 19038233-0 2009 trans-Resveratrol inhibits H2O2-induced adenocarcinoma gastric cells proliferation via inactivation of MEK1/2-ERK1/2-c-Jun signalling axis. Resveratrol 0-17 mitogen-activated protein kinase 3 Homo sapiens 110-116 19416633-8 2009 In activated HMC-1 cells, phosphorylation of extra-signal response kinase (ERK) 1/2 decreased after treatment with resveratrol. Resveratrol 115-126 mitogen-activated protein kinase 3 Homo sapiens 45-83 19416633-10 2009 Resveratrol suppressed the expression of TNF-alpha, IL-6, IL-8 and COX-2 through a decrease in the intracellular levels of Ca2+ and ERK 1/2, as well as activation of NF-kappaB. Resveratrol 0-11 mitogen-activated protein kinase 3 Homo sapiens 132-139 18296501-8 2008 Depletion of endogenous ER alpha, not ERbeta, by siRNA attenuated resveratrol- and E(2)-induced ERK1/2, Src, and eNOS phosphorylation. Resveratrol 66-77 mitogen-activated protein kinase 3 Homo sapiens 96-102 18567737-7 2008 Interestingly, resveratrol increased the activity of protein tyrosine phosphatase PTP1B, which dephosphorylates PDGF-stimulated phosphorylation at tyrosine-751 and tyrosine-716 on PDGFR with concomitant reduction in Akt and Erk1/2 kinase activity. Resveratrol 15-26 mitogen-activated protein kinase 3 Homo sapiens 224-230 18776917-5 2008 The effect of trans-resveratrol on the inhibition of p38 and ERK1/2 activation was examined. Resveratrol 14-31 mitogen-activated protein kinase 3 Homo sapiens 61-67 18776917-11 2008 trans-Resveratrol potently inhibited p38 and ERK1/2 activation after calcium ionophore and CB and C5a activation. Resveratrol 0-17 mitogen-activated protein kinase 3 Homo sapiens 45-51 18647594-0 2008 Resveratrol inhibits EMMPRIN expression via P38 and ERK1/2 pathways in PMA-induced THP-1 cells. Resveratrol 0-11 mitogen-activated protein kinase 3 Homo sapiens 52-58 18647594-4 2008 We thus investigated the role of the MAPK signaling pathway in resveratrol inhibiting the up-regulation of EMMPRIN in PMA-induced THP-1 cells. Resveratrol 63-74 mitogen-activated protein kinase 3 Homo sapiens 37-41 18647594-6 2008 We also observed that while resveratrol suppresses the up-regulation of EMMPRIN, it also suppresses both the ERK1/2 and p38 pathways in a dose-dependent manner. Resveratrol 28-39 mitogen-activated protein kinase 3 Homo sapiens 109-115 18647594-7 2008 Taken together, we established that it is through both the ERK1/2 and p38 MAPK pathways that resveratrol inhibits the expression of EMMPRIN in PMA-induced THP-1 cells. Resveratrol 93-104 mitogen-activated protein kinase 3 Homo sapiens 59-65 18575753-0 2008 ERK1/2 activation is required for resveratrol-induced apoptosis in MDA-MB-231 cells. Resveratrol 34-45 mitogen-activated protein kinase 3 Homo sapiens 0-6 18446786-3 2008 UMSCC-22B cells treated with resveratrol for 24 h, with or without selected inhibitors, were examined: (1) for the presence of nuclear activated ERK1/2, p53 and COX-2, (2) for evidence of apoptosis, and (3) by chromatin immunoprecipitation to demonstrate p53 binding to the p21 promoter. Resveratrol 29-40 mitogen-activated protein kinase 3 Homo sapiens 145-151 18446786-7 2008 Resveratrol-induced nuclear COX-2 accumulation was dependent upon ERK1/2 activation, but not p53 activation. Resveratrol 0-11 mitogen-activated protein kinase 3 Homo sapiens 66-72 18446786-9 2008 In UMSCC-22B cells, resveratrol-induced apoptosis and induction of nuclear COX-2 accumulation share dependence on the ERK1/2 signal transduction pathway. Resveratrol 20-31 mitogen-activated protein kinase 3 Homo sapiens 118-124 18575753-7 2008 Inhibition of ERK1/2 activation by its specific inhibitor or small interfering RNA reverses the effect of RSVL on Bcl-2 suppression and inhibits apoptosis, while overexpression of MEK1, which is directly upstream of both ERK1 and ERK2, enhances apoptosis induced by RSVL. Resveratrol 266-270 mitogen-activated protein kinase 3 Homo sapiens 14-18 18575753-10 2008 These results suggest that activation of ERK1/2 is required for RSVL-induced apoptosis in MDA-MB-231 cells. Resveratrol 64-68 mitogen-activated protein kinase 3 Homo sapiens 41-47 18575753-6 2008 We found that RSVL-induced apoptosis correlates with sustained activation of ERK1/2 and suppression of Bcl-2 expression. Resveratrol 14-18 mitogen-activated protein kinase 3 Homo sapiens 77-83 18575753-7 2008 Inhibition of ERK1/2 activation by its specific inhibitor or small interfering RNA reverses the effect of RSVL on Bcl-2 suppression and inhibits apoptosis, while overexpression of MEK1, which is directly upstream of both ERK1 and ERK2, enhances apoptosis induced by RSVL. Resveratrol 106-110 mitogen-activated protein kinase 3 Homo sapiens 14-20 18575753-7 2008 Inhibition of ERK1/2 activation by its specific inhibitor or small interfering RNA reverses the effect of RSVL on Bcl-2 suppression and inhibits apoptosis, while overexpression of MEK1, which is directly upstream of both ERK1 and ERK2, enhances apoptosis induced by RSVL. Resveratrol 106-110 mitogen-activated protein kinase 3 Homo sapiens 14-18 18575753-7 2008 Inhibition of ERK1/2 activation by its specific inhibitor or small interfering RNA reverses the effect of RSVL on Bcl-2 suppression and inhibits apoptosis, while overexpression of MEK1, which is directly upstream of both ERK1 and ERK2, enhances apoptosis induced by RSVL. Resveratrol 266-270 mitogen-activated protein kinase 3 Homo sapiens 14-20 17651959-14 2008 Furthermore, resveratrol significantly suppressed HRG-beta1-mediated phosphorylation of ERK1/2 and invasion of breast cancer cells. Resveratrol 13-24 mitogen-activated protein kinase 3 Homo sapiens 88-94 17651959-17 2008 The inhibitory effects of resveratrol on MMP-9 expression and invasion of breast cancer cells are, in part, associated with the down-regulation of the MAPK/ERK signaling pathway. Resveratrol 26-37 mitogen-activated protein kinase 3 Homo sapiens 151-155 17689939-0 2007 Resveratrol enhances proliferation and osteoblastic differentiation in human mesenchymal stem cells via ER-dependent ERK1/2 activation. Resveratrol 0-11 mitogen-activated protein kinase 3 Homo sapiens 117-123 18164958-2 2008 METHODS: Activity for ERK1/2 and the kinase-G cascade were determined and correlated with HCSMC count before and after treatment with HP and/or RSVL. Resveratrol 144-148 mitogen-activated protein kinase 3 Homo sapiens 22-28 18164958-5 2008 RSVL (1-100 microM) elicited more prominent inhibition of HP-evoked cell proliferation and ERK1/2 activation. Resveratrol 0-4 mitogen-activated protein kinase 3 Homo sapiens 91-97 18164958-8 2008 CONCLUSIONS: Collectively, RSVL activates the kinase-G system to counteract HP-induced ERK1/2 activation and coronary arterial proliferation. Resveratrol 27-31 mitogen-activated protein kinase 3 Homo sapiens 87-93 17689939-3 2007 Further studies found that RSVL (10(-6)M) resulted in a rapid activation of both extracellular signal-regulated kinase 1/2 (ERK1/2) and p38 mitogen-activated protein kinase (MAPK) signaling in HBMSCs cultures. Resveratrol 27-31 mitogen-activated protein kinase 3 Homo sapiens 124-130 17689939-3 2007 Further studies found that RSVL (10(-6)M) resulted in a rapid activation of both extracellular signal-regulated kinase 1/2 (ERK1/2) and p38 mitogen-activated protein kinase (MAPK) signaling in HBMSCs cultures. Resveratrol 27-31 mitogen-activated protein kinase 3 Homo sapiens 174-178 20641411-8 2004 Several research studies have reported that resveratrol has the ability to induce p53-dependent apoptosis in several cancer cell lines, and that the signal transduction pathways implicated in resveratrol action includes those of extracellular-regulated kinases 1 and 2 (ERK1/2), p38 kinase, and Jun N-terminal kinase (JNK) (6, 7). Resveratrol 192-203 mitogen-activated protein kinase 3 Homo sapiens 270-276 17689939-5 2007 An ERK1/2 pathway inhibitor, PD98059, significantly attenuated RSVL-induced ERK1/2 phosphorylation, consistent with the reduction of cell proliferation and osteoblastic differentiation as well as expression of osteoblastic markers. Resveratrol 63-67 mitogen-activated protein kinase 3 Homo sapiens 3-9 17689939-5 2007 An ERK1/2 pathway inhibitor, PD98059, significantly attenuated RSVL-induced ERK1/2 phosphorylation, consistent with the reduction of cell proliferation and osteoblastic differentiation as well as expression of osteoblastic markers. Resveratrol 63-67 mitogen-activated protein kinase 3 Homo sapiens 76-82 17689939-6 2007 In contrast, SB203580, a p38 MAPK pathway blocker, blocked RSVL-induced p38 phosphorylation, but resulted in an increase of cell proliferation and a more osteoblastic maturation. Resveratrol 59-63 mitogen-activated protein kinase 3 Homo sapiens 29-33 17689939-7 2007 These data suggest that RSVL stimulates HBMSCs proliferation and osteoblastic differentiation through an ER-dependent mechanism and coupling to ERK1/2 activation. Resveratrol 24-28 mitogen-activated protein kinase 3 Homo sapiens 144-150 16860989-7 2006 Immunoblotting revealed that resveratrol 50 microM induced the phosphorylation/activation of Akt and extracellular signal-regulated kinase-1 and -2 (ERK1/2) and the phosphorylation/inactivation of glycogen synthase kinase-3beta (GSK-3beta). Resveratrol 29-40 mitogen-activated protein kinase 3 Homo sapiens 149-155 16790523-3 2006 This receptor is linked to induction by resveratrol of extracellular-regulated kinases 1 and 2 (ERK1/2)- and serine-15-p53-dependent phosphorylation leading to apoptosis. Resveratrol 40-51 mitogen-activated protein kinase 3 Homo sapiens 96-102 16790523-4 2006 The integrin receptor is near the Arg-Gly-Asp (RGD) recognition site on the integrin; an integrin-binding RGD peptide inhibits induction by resveratrol of ERK1/2- and p53-dependent apoptosis. Resveratrol 140-151 mitogen-activated protein kinase 3 Homo sapiens 155-161 16790523-5 2006 Antibody (Ab) to integrin alphaVbeta3, but not to alphaVbeta5, inhibits activation by resveratrol of ERK1/2 and p53 and consequent apoptosis in estrogen receptor-alpha (ERalpha) positive MCF-7, and ERalpha-negative MDA-MB231 cells. Resveratrol 86-97 mitogen-activated protein kinase 3 Homo sapiens 101-107 16860989-5 2006 To elucidate a possible mechanism by which resveratrol exerts its neuroprotective effect, we investigated the phosphoinositide3-kinase (PI3-k) pathway using LY294002 (5 microM) and mitogen-activated protein kinase (MAPK) using PD98059 (20 microM). Resveratrol 43-54 mitogen-activated protein kinase 3 Homo sapiens 215-219 15498824-5 2005 Pretreatment of CFs with RES (5-25 microM) inhibited basal and ANG II-induced extracellular signal-regulated kinase (ERK) 1/2 and ERK kinase activation. Resveratrol 25-28 mitogen-activated protein kinase 3 Homo sapiens 78-125 16928824-4 2006 The induction of COX-2 accumulation by resveratrol is mitogen-activated protein kinase (MAPK; extracellular signal-regulated kinase 1/2)- and activator protein 1- dependent. Resveratrol 39-50 mitogen-activated protein kinase 3 Homo sapiens 88-92 16814113-0 2006 Potent antiproliferative effects of resveratrol on human osteosarcoma SJSA1 cells: Novel cellular mechanisms involving the ERKs/p53 cascade. Resveratrol 36-47 mitogen-activated protein kinase 3 Homo sapiens 123-127 16814113-3 2006 In this study, we investigated the involvement of the mitogen activated protein kinase (MAPK)/p53 signal transduction mechanism in RSVL-induced growth inhibition using a human osteosarcoma cell line. Resveratrol 131-135 mitogen-activated protein kinase 3 Homo sapiens 88-92 16814113-9 2006 The effects of RSVL on ERKs and on p53 phosphorylation were abrogated by either the MAPK inhibitor PD98059 or the p53 inhibitor pifithrine-alpha. Resveratrol 15-19 mitogen-activated protein kinase 3 Homo sapiens 23-27 16814113-9 2006 The effects of RSVL on ERKs and on p53 phosphorylation were abrogated by either the MAPK inhibitor PD98059 or the p53 inhibitor pifithrine-alpha. Resveratrol 15-19 mitogen-activated protein kinase 3 Homo sapiens 84-88 16814113-10 2006 The present study indicates that RSVL antiproliferative effects on osteosarcoma cells are mediated by the activation of the ERKs/p53 signaling pathway and therefore identifies new targets for strategies to treat and/or prevent osteosarcoma. Resveratrol 33-37 mitogen-activated protein kinase 3 Homo sapiens 124-128 16928824-6 2006 The interaction of COX-2, p53, and p300, as well as resveratrol-induced apoptosis, was inhibited by a MAPK activation inhibitor, PD98059. Resveratrol 52-63 mitogen-activated protein kinase 3 Homo sapiens 102-106 16761963-4 2006 Resveratrol inhibited mitogen-activated protein kinase/extracellular signal-regulated kinase kinase (MEK)1 > extracellular signal-regulated protein kinase (ERK)1/2 signalling, downregulated c-Jun, and suppressed activating protein (AP)-1 DNA-binding and promoter activity. Resveratrol 0-11 mitogen-activated protein kinase 3 Homo sapiens 112-166 15188005-3 2004 Treatment of MCF-7 cells with resveratrol in the presence of 17beta-oestradiol (E(2)) further enhanced MAPK activation, but E(2) blocked resveratrol-induced apoptosis, as measured by nucleosome ELISA and DNA fragmentation assays. Resveratrol 30-41 mitogen-activated protein kinase 3 Homo sapiens 103-107 15542774-1 2004 Resveratrol, a naturally occurring stilbene with antitumor properties, caused mitogen-activated protein kinase [MAPK, extracellular signal-regulated kinase 1/2 (ERK1/2)] activation, nuclear translocation of Ser15-phosphorylated p53, and p53-dependent apoptosis in hormone-insensitive DU145 prostate cancer cells. Resveratrol 0-11 mitogen-activated protein kinase 3 Homo sapiens 112-116 15542774-1 2004 Resveratrol, a naturally occurring stilbene with antitumor properties, caused mitogen-activated protein kinase [MAPK, extracellular signal-regulated kinase 1/2 (ERK1/2)] activation, nuclear translocation of Ser15-phosphorylated p53, and p53-dependent apoptosis in hormone-insensitive DU145 prostate cancer cells. Resveratrol 0-11 mitogen-activated protein kinase 3 Homo sapiens 161-167 15542774-7 2004 DU145 cells transfected with a dominant-negative PKC-alpha construct showed resveratrol-induced ERK1/2 phosphorylation and Ser15 phosphorylation of p53 but were unresponsive to EGF. Resveratrol 76-87 mitogen-activated protein kinase 3 Homo sapiens 96-102 15542774-8 2004 Thus, resveratrol and EGF activate MAPK by discrete mechanisms in DU145 cells. Resveratrol 6-17 mitogen-activated protein kinase 3 Homo sapiens 35-39 15698585-9 2005 The observed reduction in cell proliferation was associated with inhibition of mitogen activated protein kinase/ERK (MEK) and extracellular signal-regulated kinase (ERK 1/2) activities at concentrations of resveratrol as low as 5 micromol/L. Resveratrol 206-217 mitogen-activated protein kinase 3 Homo sapiens 112-115 15698585-9 2005 The observed reduction in cell proliferation was associated with inhibition of mitogen activated protein kinase/ERK (MEK) and extracellular signal-regulated kinase (ERK 1/2) activities at concentrations of resveratrol as low as 5 micromol/L. Resveratrol 206-217 mitogen-activated protein kinase 3 Homo sapiens 165-172 15542774-11 2004 Inhibition of PKC activation in LNCaP cells, however, resulted in a reduction, rather than increase, in p53 activation and apoptosis, suggesting that resveratrol-induced apoptosis in these two cell lines occurs through different PKC-mediated and MAPK-dependent pathways. Resveratrol 150-161 mitogen-activated protein kinase 3 Homo sapiens 246-250 14739659-0 2004 Resveratrol antagonizes EGFR-dependent Erk1/2 activation in human androgen-independent prostate cancer cells with associated isozyme-selective PKC alpha inhibition. Resveratrol 0-11 mitogen-activated protein kinase 3 Homo sapiens 39-45 14739659-2 2004 In this report, we show that growth-inhibitory concentrations of the dietary phytochemical resveratrol suppress EGFR-dependent Erk1/2 activation pathways stimulated by EGF and phorbol ester (12- O -tetradecanoyl phorbol 13-acetate, TPA) in human AI PrCa PC-3 cells in vitro. Resveratrol 91-102 mitogen-activated protein kinase 3 Homo sapiens 127-133 14739659-7 2004 Under conditions where resveratrol suppressed TPA-induced Erk1/2 activation, the phytochemical produced isozyme-selective interference with TPA-induced translocation of cytosolic PKCalpha to the membrane/cytoskeleton and selectively diminished the amount of autophosphorylated PKCalpha in the membrane/cytoskeleton of the TPA-treated cells. Resveratrol 23-34 mitogen-activated protein kinase 3 Homo sapiens 58-64 14739659-8 2004 These results demonstrate that resveratrol abrogation of a PKC-mediated Erk1/2 activation response in PC-3 cells correlates with isozyme-selective PKCalpha inhibition. Resveratrol 31-42 mitogen-activated protein kinase 3 Homo sapiens 72-78 14749477-11 2004 Inhibition of Bcl-x(L) expression by resveratrol was due to the inhibition of the extracellular signal-regulated kinase 1/2 (ERK1/2) pathway and diminished activator protein-1-dependent Bcl-x(L) expression. Resveratrol 37-48 mitogen-activated protein kinase 3 Homo sapiens 125-131 14749477-12 2004 The findings by resveratrol were corroborated with inhibitors of the ERK1/2 pathway. Resveratrol 16-27 mitogen-activated protein kinase 3 Homo sapiens 69-75 34299258-0 2021 Resveratrol Is a Natural Inhibitor of Human Intestinal Mast Cell Activation and Phosphorylation of Mitochondrial ERK1/2 and STAT3. Resveratrol 0-11 mitogen-activated protein kinase 3 Homo sapiens 113-119 14623829-5 2003 Resveratrol also inhibits strain-increased NADPH oxidase activity, reactive oxygen species formation, and extracellular signal-regulated kinases1/2 (ERK1/2) phosphorylation. Resveratrol 0-11 mitogen-activated protein kinase 3 Homo sapiens 149-155 14623829-6 2003 Furthermore, pretreating cells with resveratrol or antioxidant N-acetyl-cysteine decreases strain-increased or hydrogen peroxide-increased ET-1 secretion, ET-1 promoter activity, and ET-1 mRNA and ERK1/2 phosphorylation. Resveratrol 36-47 mitogen-activated protein kinase 3 Homo sapiens 197-203 14623829-8 2003 In summary, we demonstrate for the first time that resveratrol inhibits strain-induced ET-1 gene expression, partially by interfering with the ERK1/2 pathway through attenuation of reactive oxygen species formation. Resveratrol 51-62 mitogen-activated protein kinase 3 Homo sapiens 143-149 12690110-5 2003 The quantitative analysis of some transcription factors involved in the erythroid lineage, namely GATA-1, GATA-2, and Egr1, indicated that resveratrol selectively up-regulates Egr1 by an Erk1/2-dependent mechanism. Resveratrol 139-150 mitogen-activated protein kinase 3 Homo sapiens 187-193 12565170-7 2003 Although resveratrol did not alter the phosphorylation of p38 or JNK MAP kinases in either cell line, it induced phosphorylation of ERK1/2 in A375, but not in SK-mel28 cells. Resveratrol 9-20 mitogen-activated protein kinase 3 Homo sapiens 132-138 11889192-0 2002 Resveratrol induces apoptosis in thyroid cancer cell lines via a MAPK- and p53-dependent mechanism. Resveratrol 0-11 mitogen-activated protein kinase 3 Homo sapiens 65-69 11889192-1 2002 Two papillary thyroid carcinoma (PTC) and two follicular thyroid carcinoma (FTC) cell lines treated with resveratrol (RV), 1-10 microM, showed activation and nuclear translocation of MAPK (extracellular signal-regulated kinase 1/2). Resveratrol 105-116 mitogen-activated protein kinase 3 Homo sapiens 183-187 11889192-1 2002 Two papillary thyroid carcinoma (PTC) and two follicular thyroid carcinoma (FTC) cell lines treated with resveratrol (RV), 1-10 microM, showed activation and nuclear translocation of MAPK (extracellular signal-regulated kinase 1/2). Resveratrol 105-116 mitogen-activated protein kinase 3 Homo sapiens 189-230 11889192-1 2002 Two papillary thyroid carcinoma (PTC) and two follicular thyroid carcinoma (FTC) cell lines treated with resveratrol (RV), 1-10 microM, showed activation and nuclear translocation of MAPK (extracellular signal-regulated kinase 1/2). Resveratrol 118-120 mitogen-activated protein kinase 3 Homo sapiens 183-187 11889192-1 2002 Two papillary thyroid carcinoma (PTC) and two follicular thyroid carcinoma (FTC) cell lines treated with resveratrol (RV), 1-10 microM, showed activation and nuclear translocation of MAPK (extracellular signal-regulated kinase 1/2). Resveratrol 118-120 mitogen-activated protein kinase 3 Homo sapiens 189-230 11709203-3 2001 We determined the action of resveratrol on cellular function and cellular integrity by measuring DNA synthesis, cellular proliferation, cell cycle distribution, cytolysis, apoptosis, and phosphotransferase activities of two key signaling enzymes, protein kinase C (PKC) and mitogen-activated protein kinases (ERK1/ERK2), in human gastric adenocarcinoma KATO-III and RF-1 cells. Resveratrol 28-39 mitogen-activated protein kinase 3 Homo sapiens 309-313 10320034-2 1999 In undifferentiated cells resveratrol 1 microM induced phosphorylation of ERK1 and ERK2, which was already evident at 2 min, peaked at 10 min and persisted at 30 min. Resveratrol 26-37 mitogen-activated protein kinase 3 Homo sapiens 74-78 10320034-3 1999 A wide range (from 1 pM to 10 microM) of resveratrol concentrations were able to induce phosphorylation of ERK1 and ERK2, while higher concentrations (50-100 microM) inhibited MAP kinases phosphorylation. Resveratrol 41-52 mitogen-activated protein kinase 3 Homo sapiens 107-111 10320034-4 1999 In retinoic acid (RA) differentiated cells resveratrol (1 microM) induced an evident increase in ERK1 and ERK2 phosphorylation. Resveratrol 43-54 mitogen-activated protein kinase 3 Homo sapiens 97-101 34966970-6 2021 In triethylsilyl resveratrol treated cells a marked increase in ERK1/2 phosphorylation was observed compared to the control cells. Resveratrol 17-28 mitogen-activated protein kinase 3 Homo sapiens 64-70 10356984-0 1999 Resveratrol inhibits MAPK activity and nuclear translocation in coronary artery smooth muscle: reversal of endothelin-1 stimulatory effects. Resveratrol 0-11 mitogen-activated protein kinase 3 Homo sapiens 21-25 10356984-1 1999 In porcine coronary arteries, short-term treatment with resveratrol (RSVL) substantially inhibited MAPK activity (IC50 = 37 microM); and immunoblot analyses revealed consistent reduction in the phosphorylation of ERK-1/-2, JNK-1 and p38, at active sites. Resveratrol 56-67 mitogen-activated protein kinase 3 Homo sapiens 99-103 10356984-1 1999 In porcine coronary arteries, short-term treatment with resveratrol (RSVL) substantially inhibited MAPK activity (IC50 = 37 microM); and immunoblot analyses revealed consistent reduction in the phosphorylation of ERK-1/-2, JNK-1 and p38, at active sites. Resveratrol 56-67 mitogen-activated protein kinase 3 Homo sapiens 213-221 10356984-1 1999 In porcine coronary arteries, short-term treatment with resveratrol (RSVL) substantially inhibited MAPK activity (IC50 = 37 microM); and immunoblot analyses revealed consistent reduction in the phosphorylation of ERK-1/-2, JNK-1 and p38, at active sites. Resveratrol 69-73 mitogen-activated protein kinase 3 Homo sapiens 99-103 10356984-1 1999 In porcine coronary arteries, short-term treatment with resveratrol (RSVL) substantially inhibited MAPK activity (IC50 = 37 microM); and immunoblot analyses revealed consistent reduction in the phosphorylation of ERK-1/-2, JNK-1 and p38, at active sites. Resveratrol 69-73 mitogen-activated protein kinase 3 Homo sapiens 213-221 10356984-4 1999 Likewise, inhibition of MAPK by RSVL was not reversed by the estrogen receptor blockers tamoxifen and ICI-182,780. Resveratrol 32-36 mitogen-activated protein kinase 3 Homo sapiens 24-28 10320034-0 1999 Resveratrol-induced activation of the mitogen-activated protein kinases, ERK1 and ERK2, in human neuroblastoma SH-SY5Y cells. Resveratrol 0-11 mitogen-activated protein kinase 3 Homo sapiens 73-77 10320034-1 1999 Phosphorylation of the mitogen-activated protein (MAP) kinases, extracellular signal-regulated kinase 1 (ERK1) and extracellular signal-regulated kinase 2 (ERK2), induced by resveratrol, a natural antioxidant present in grapes and wine, has been studied in vitro on undifferentiated and differentiated (induction by retinoic acid) SH-SY5Y human neuroblastoma cells. Resveratrol 174-185 mitogen-activated protein kinase 3 Homo sapiens 105-109 10370870-5 1999 We have shown that resveratrol induces phosphorylation of the mitogen-activated protein (MAP) kinase family members, extracellular regulated kinase 1 (ERK1) and ERK2, in the human neuroblastoma SH-SY5Y cells in vitro at much lower concentrations than those found in the plasma of rats after oral wine administration. Resveratrol 19-30 mitogen-activated protein kinase 3 Homo sapiens 117-149 10370870-5 1999 We have shown that resveratrol induces phosphorylation of the mitogen-activated protein (MAP) kinase family members, extracellular regulated kinase 1 (ERK1) and ERK2, in the human neuroblastoma SH-SY5Y cells in vitro at much lower concentrations than those found in the plasma of rats after oral wine administration. Resveratrol 19-30 mitogen-activated protein kinase 3 Homo sapiens 151-155 34299258-6 2021 Further, resveratrol inhibited the phosphorylation of extracellular signal-regulated kinase (ERK) 1/2 and signal transducer and activator of transcription (STAT) 3. Resveratrol 9-20 mitogen-activated protein kinase 3 Homo sapiens 54-101 34299258-9 2021 We were able to isolate mitochondrial fractions from small hiMC numbers and could show that activation of mitochondrial STAT3 and ERK1/2 in hiMC was also inhibited by resveratrol. Resveratrol 167-178 mitogen-activated protein kinase 3 Homo sapiens 130-136 34299258-10 2021 Our results indicate that resveratrol inhibits hiMC activation by inhibiting the phosphorylation of mitochondrial and nuclear ERK1/2 and STAT3, and it could be considered as an anti-inflammatory nutraceutical in the treatment of mast cell-associated diseases. Resveratrol 26-37 mitogen-activated protein kinase 3 Homo sapiens 126-132 34073143-5 2021 In addition, resveratrol treatment suppressed the phosphorylation of phosphatidylinositol 3-kinase/AKT and extracellular signal-regulated kinase 1/2. Resveratrol 13-24 mitogen-activated protein kinase 3 Homo sapiens 107-148 33204396-14 2020 We found seven putative genes predicted to be modulated by Rsv in the context of Doxo treatment: CCND1, CDH1, ESR1, HSP90AA1, MAPK3, PTPN11, and RPS6KB1. Resveratrol 59-62 mitogen-activated protein kinase 3 Homo sapiens 126-131 33249095-8 2021 The p-ERK1/2 was increased by ~2.5-fold and ~1.5-fold upon 50 muM genistein and 15 muM resveratrol treatments at 24 h, respectively. Resveratrol 87-98 mitogen-activated protein kinase 3 Homo sapiens 6-12 32798507-6 2020 The results showed that the effect of resveratrol may be closely associated with targets such as AKT serine/threonine kinase 1 (AKT1), mitogen-activated protein kinase 3 (MAPK3), Sirtuin-1 (SIRT1) and proto-oncogene tyrosine-protein kinase Src (SRC), as well as biological processes such as cell proliferation, inflammatory response, and redox balance. Resveratrol 38-49 mitogen-activated protein kinase 3 Homo sapiens 135-169 32798507-6 2020 The results showed that the effect of resveratrol may be closely associated with targets such as AKT serine/threonine kinase 1 (AKT1), mitogen-activated protein kinase 3 (MAPK3), Sirtuin-1 (SIRT1) and proto-oncogene tyrosine-protein kinase Src (SRC), as well as biological processes such as cell proliferation, inflammatory response, and redox balance. Resveratrol 38-49 mitogen-activated protein kinase 3 Homo sapiens 171-176 33139717-5 2020 RSV was able to inhibit lipopolysaccharide (LPS) stimulated inflammatory responses through blocking Phospholipase D (PLD) and its downstream signaling molecules SphK1, ERK1/2 and NF-kappaB. Resveratrol 0-3 mitogen-activated protein kinase 3 Homo sapiens 168-174